பிரிவு ஆஃப் கல்லீரல் நோய்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பிரிவு ஆஃப் கல்லீரல் நோய்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பிரிவு ஆஃப் கல்லீரல் நோய்கள் Today - Breaking & Trending Today

Can-Fite Reports on Progress With Its Namodenoson NASH Program


Can-Fite Reports on Progress With Its Namodenoson NASH Program
Can-Fite Reports on Progress With Its Namodenoson NASH Program
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the following progress with its Namodenoson drug candidate for non-alcoholic steatohepatitis (NASH) treatment:
The Company is currently engaged in the design of a Phase IIb study for Namodenoson in the treatment of NASH. The protocol is being developed in conjunction with leading Key Opinion Leaders (KOLs) in NASH and liver diseases including Dr. Scott Friedman, Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York, and Dr. Stephen A. Harrison, Medical Director of Pinnacle Clinical Research, both of whom were involved in the design of Namodenosons successfully completed Phase II study in NAFLD ....

New York , United States , Fite Biopharma , Motti Farbstein , Pnina Fishman , Stephena Harrison , Scott Friedman , Exchange Commission , Division Of Liver Diseases , Pinnacle Clinical Research , Icahn School Of Medicine At Mount Sinai , Fite Biopharma Ltd , Drug Administration , Can Fite Biopharma , Key Opinion Leaders , Liver Diseases , Icahn School , Mount Sinai , Medical Director , Orphan Drug Designation , Fast Track Designation , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , மொட்டி பார்பிசிதஎன் , ப்ணிந மீன் , ஸ்காட் ப்ரைட்மேன் ,

Can-Fite Reports on Progress With Its Namodenoson NASH Program


Share:
Manufacturing of Namodenoson for the Phase IIb study is completed
NASH patents are now issued in U.S. & Europe
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the following progress with its Namodenoson drug candidate for non-alcoholic steatohepatitis (NASH) treatment:
The Company is currently engaged in the design of a Phase IIb study for Namodenoson in the treatment of NASH. The protocol is being developed in conjunction with leading Key Opinion Leaders (KOLs) in NASH and liver diseases including Dr. Scott Friedman, Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York, and Dr. Stephen A. Harrison, Medical Director of Pinnacle Clinical Research, both of whom were involved in the design of Namodenoson s successfully completed Phase II study in NAFLD/NASH which ach ....

New York , United States , Pnina Fishman , Stephena Harrison , Scott Friedman , Exchange Commission , Division Of Liver Diseases , Pinnacle Clinical Research , Icahn School Of Medicine At Mount Sinai , Fite Biopharma Ltd , Drug Administration , Opinion Leaders , Fite Biopharma , Key Opinion Leaders , Liver Diseases , Icahn School , Mount Sinai , Medical Director , Orphan Drug Designation , Fast Track Designation , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ப்ணிந மீன் , ஸ்காட் ப்ரைட்மேன் , பரிமாற்றம் தரகு , பிரிவு ஆஃப் கல்லீரல் நோய்கள் ,

Can-Fite BioPharma Ltd.: Can-Fite Reports on Progress With Its Namodenoson NASH Program


Can-Fite BioPharma Ltd.: Can-Fite Reports on Progress With Its Namodenoson NASH Program
Manufacturing of Namodenoson for the Phase IIb study is completed
NASH patents are now issued in U.S. Europe
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the following progress with its Namodenoson drug candidate for non-alcoholic steatohepatitis (NASH) treatment:
The Company is currently engaged in the design of a Phase IIb study for Namodenoson in the treatment of NASH. The protocol is being developed in conjunction with leading Key Opinion Leaders (KOLs) in NASH and liver diseases including Dr. Scott Friedman, Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York, and Dr. Stephen A. Harrison, Medical Director of Pinnacle Clinical Research, both of whom were involve ....

New York , United States , Fite Biopharma , Motti Farbstein , Pnina Fishman , Stephena Harrison , Scott Friedman , Exchange Commission , Division Of Liver Diseases , Pinnacle Clinical Research , Icahn School Of Medicine At Mount Sinai , Fite Biopharma Ltd , Drug Administration , Opinion Leaders , Key Opinion Leaders , Liver Diseases , Icahn School , Mount Sinai , Medical Director , Orphan Drug Designation , Fast Track Designation , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , மொட்டி பார்பிசிதஎன் , ப்ணிந மீன் , ஸ்காட் ப்ரைட்மேன் ,